PE20050712A1 - Anticuerpos rg1 - Google Patents
Anticuerpos rg1Info
- Publication number
- PE20050712A1 PE20050712A1 PE2004000690A PE2004000690A PE20050712A1 PE 20050712 A1 PE20050712 A1 PE 20050712A1 PE 2004000690 A PE2004000690 A PE 2004000690A PE 2004000690 A PE2004000690 A PE 2004000690A PE 20050712 A1 PE20050712 A1 PE 20050712A1
- Authority
- PE
- Peru
- Prior art keywords
- antibodies
- seq
- refers
- polypeptide
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Abstract
SE REFIERE A ANTICUERPOS, O FRAGMENTOS DE ANTICUERPOS DE UNION AL ANTIGENO DEL MISMO O VARIANTES DEL MISMO, QUE SE UNEN AL EPITOPE DEL POLIPEPTIDO RG1(SEQ ID N°2) CON UNA CONSTANTE DE DISOCIACION (KD) MENOR O IGUAL A 1uM. ESTOS ANTICUERPOS AISLADOS O FRAGMENTOS DE ANTICUERPOS COMPRENDEN UNA REGION VARIABLE EN LA CADENA LIVIANA QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE LAS SEQ ID N° 26 O SEQ ID N° 29, Y UNA REGION VARIABLE DE LA CADENA PESADA QUE COMPRENDE LAS SECUENCIAS SQ ID N° 27, SQ ID N° 28, SQ ID N° 30, SQ ID N° 31. TAMBIEN SE REFIERE A UN ANTICUERPO QUE COMPRENDE LA SQ ID N° 21, SQ ID N° 22, SQ ID N° 24 O SQ ID N° 25. ESTOS ANTICUERPOS SE CONJUGAN CON UN MARCADOR DETECTABLE PARA SU USO COMO AGENTE DE DIAGNOSTICO. TAMBIEN SE REFIERE A UN METODO DE DETECCION Y TRATAMIENTO DE UN ESTADO DE ENFERMEDAD ASOCIADO CON LA EXPRESION DE UN POLIPEPTIDO RG1, TAL COMO CANCER DE PROSTATA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48903203P | 2003-07-22 | 2003-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050712A1 true PE20050712A1 (es) | 2005-11-02 |
Family
ID=34102813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000690A PE20050712A1 (es) | 2003-07-22 | 2004-07-20 | Anticuerpos rg1 |
Country Status (22)
Country | Link |
---|---|
US (4) | US7335748B2 (es) |
EP (1) | EP1648510B1 (es) |
JP (1) | JP4680902B2 (es) |
KR (1) | KR101215218B1 (es) |
CN (1) | CN1826138B (es) |
AU (1) | AU2004259731B2 (es) |
BR (1) | BRPI0412245A (es) |
CA (1) | CA2532394C (es) |
CR (1) | CR8231A (es) |
EC (1) | ECSP066379A (es) |
ES (1) | ES2427544T3 (es) |
GT (1) | GT200400138A (es) |
IL (1) | IL172871A (es) |
MX (1) | MXPA06000798A (es) |
NO (1) | NO20060843L (es) |
NZ (1) | NZ544911A (es) |
PE (1) | PE20050712A1 (es) |
RU (1) | RU2377252C2 (es) |
TW (1) | TWI353992B (es) |
UY (1) | UY28424A1 (es) |
WO (1) | WO2005010048A2 (es) |
ZA (1) | ZA200601521B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4680902B2 (ja) * | 2003-07-22 | 2011-05-11 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Rg1抗体及びその使用 |
US7294704B2 (en) | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
CL2008003525A1 (es) * | 2007-11-30 | 2010-01-22 | Medarex Inc | Conjugado de anticuerpo monoclonal humano anti-rg1 o una porcion de union a antigeno del mismo con moleculas asociadas, composicion que lo comprende; metodo in vitro para inhibir el crecimiento de una celula tumoral que expresa rg-1; uso de dicho conjugado para tratar el cancer |
US20110059091A1 (en) * | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
CN103201287B (zh) * | 2010-08-12 | 2016-04-13 | 艾托生物有限公司 | 成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途 |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
MX350539B (es) | 2012-02-13 | 2017-09-08 | Bristol Myers Squibb Co | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. |
RS56169B1 (sr) | 2013-02-14 | 2017-11-30 | Bristol Myers Squibb Co | Jedinjenja tubulisina, metode pripreme i primena |
JP6474404B2 (ja) | 2013-08-14 | 2019-02-27 | ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 |
CA2948699C (en) | 2014-05-13 | 2019-11-26 | Paul Scherrer Institut | Production of 43sc radionuclide and radiopharmaceuticals thereof for use in positron emission tomography |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
EP3221346B1 (en) | 2014-11-21 | 2020-09-02 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
WO2016115201A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
EP3394096A1 (en) | 2015-12-21 | 2018-10-31 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
KR20190005924A (ko) | 2016-05-10 | 2019-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 향상된 안정성을 갖는 튜부리신 유사체의 항체-약물 접합체 |
KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
KR20220167342A (ko) | 2017-05-25 | 2022-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
EA202092747A1 (ru) | 2018-05-29 | 2021-03-16 | Бристол-Маерс Сквибб Компани | Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル-マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
SI3886914T1 (sl) | 2018-11-30 | 2023-06-30 | Bristol-Myers Squibb Company | Protitelo, ki vsebuje C-terminalni podaljšek lahke verige, ki vsebuje glutamin, njegove konjugate ter metode in uporabe |
US20220031860A1 (en) | 2018-12-12 | 2022-02-03 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5246692A (en) * | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5871969A (en) * | 1996-02-12 | 1999-02-16 | Human Genome Sciences, Inc. | Nucleic acids encoding human neuronal attachment factor-1 |
US6177244B1 (en) * | 1996-05-10 | 2001-01-23 | Beth Israel Deaconess Medical Center Inc. | NPG-1 gene that is differentially expressed in prostate tumors |
US6287777B1 (en) * | 1996-05-10 | 2001-09-11 | Beth Israel Deaconess Medical Center | NPG-1 gene that is differentially expressed in prostate tumors |
US5804382A (en) * | 1996-05-10 | 1998-09-08 | Beth Israel Deaconess Medical Center, Inc. | Methods for identifying differentially expressed genes and differences between genomic nucleic acid sequences |
WO1998045442A2 (en) | 1997-04-10 | 1998-10-15 | Zymogenetics, Inc. | Secreted f-spondin homologs |
EP0986400A4 (en) | 1997-05-09 | 2002-10-09 | Smithkline Beecham Corp | INTEGRIN LIGAND, HUMAN MINDIN |
PT1490386E (pt) | 1998-03-10 | 2008-11-24 | Genentech Inc | Novos polipéptidos e ácidos nucleicos que os codificam |
CA2347085A1 (en) | 1998-10-19 | 2000-04-27 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US6824780B1 (en) * | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
GB0124317D0 (en) * | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
JP4680902B2 (ja) * | 2003-07-22 | 2011-05-11 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Rg1抗体及びその使用 |
-
2004
- 2004-07-20 JP JP2006521161A patent/JP4680902B2/ja not_active Expired - Fee Related
- 2004-07-20 WO PCT/US2004/023143 patent/WO2005010048A2/en active Application Filing
- 2004-07-20 PE PE2004000690A patent/PE20050712A1/es not_active Application Discontinuation
- 2004-07-20 GT GT200400138A patent/GT200400138A/es unknown
- 2004-07-20 CA CA 2532394 patent/CA2532394C/en not_active Expired - Fee Related
- 2004-07-20 ES ES04778578T patent/ES2427544T3/es active Active
- 2004-07-20 AU AU2004259731A patent/AU2004259731B2/en not_active Ceased
- 2004-07-20 UY UY28424A patent/UY28424A1/es not_active Application Discontinuation
- 2004-07-20 TW TW93121655A patent/TWI353992B/zh not_active IP Right Cessation
- 2004-07-20 MX MXPA06000798A patent/MXPA06000798A/es active IP Right Grant
- 2004-07-20 BR BRPI0412245 patent/BRPI0412245A/pt not_active IP Right Cessation
- 2004-07-20 RU RU2006105339A patent/RU2377252C2/ru not_active IP Right Cessation
- 2004-07-20 NZ NZ544911A patent/NZ544911A/en unknown
- 2004-07-20 CN CN2004800211789A patent/CN1826138B/zh not_active Expired - Fee Related
- 2004-07-20 US US10/895,183 patent/US7335748B2/en not_active Expired - Fee Related
- 2004-07-20 EP EP04778578.7A patent/EP1648510B1/en active Active
- 2004-07-20 KR KR1020067001366A patent/KR101215218B1/ko not_active IP Right Cessation
-
2005
- 2005-12-28 IL IL17287105A patent/IL172871A/en not_active IP Right Cessation
-
2006
- 2006-02-13 CR CR8231A patent/CR8231A/es not_active Application Discontinuation
- 2006-02-16 EC ECSP066379 patent/ECSP066379A/es unknown
- 2006-02-21 ZA ZA200601521A patent/ZA200601521B/en unknown
- 2006-02-21 NO NO20060843A patent/NO20060843L/no not_active Application Discontinuation
-
2007
- 2007-10-30 US US11/981,219 patent/US7611706B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/981,123 patent/US7608263B2/en not_active Expired - Fee Related
-
2009
- 2009-09-15 US US12/560,363 patent/US20100081795A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050712A1 (es) | Anticuerpos rg1 | |
PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
PE20071055A1 (es) | Anticuerpos anti mn | |
MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
ECSP024210A (es) | Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas | |
EA200501206A1 (ru) | Производные от сурвивина пептиды и их применение | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
DE69939819D1 (de) | Verfahren zur krebsdiagnose mittels eines chimärischen toxin | |
PE20221263A1 (es) | Agentes de union a ilt3 y metodos de uso de los mismos | |
CL2019003405A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
PE20050962A1 (es) | Anticuerpos completamente humanos contra 4-1bb humano | |
BR112021025699A2 (pt) | Anticorpos anti-mesotelina e imunoconjugados dos mesmos | |
PE20240368A1 (es) | Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos | |
PE20191743A1 (es) | Anticuerpos biespecificos anti-pd-l1-anti-tim3 | |
AR069958A1 (es) | Metodo para producir una proteina heterologa de interes | |
BR112022009482A2 (pt) | Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |